RxDoctor Payments Data

Amy Steinhoff

Family · Glendale, AZNPI 1164763421

Payments from drug & device makers

$10,086in general payments, 2019–2025

Across 566 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • Amgen$983
  • AstraZeneca$790
  • Pfizer$492
  • GSK$393
  • plus $5K from 53 others

What the payments were for

  • Food & beverage$9,84598%
  • Education$2412%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie78$1,376
Novo Nordisk64$1,014
Amgen(2 entities)66$983
AstraZeneca(2 entities)23$790
Pfizer28$492
GSK24$393
Astellas Pharma US Inc16$375
Boehringer Ingelheim17$312
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC19$292
Radius Health, Inc.15$284
Nestle Healthcare Nutrition Inc.13$272
Sanofi-aventis U.S. LLC20$252
Teva Pharmaceuticals USA, Inc.10$244
Medtronic7$204
Lilly USA, LLC21$199
Edwards Lifesciences3$184
Bayer12$172
Biohaven Pharmaceuticals, Inc.10$171
Takeda Pharmaceuticals U.S.A., Inc.9$161
Recordati_rare_diseases_inc.8$155
Biohaven Pharmaceutical Holding Company Ltd.7$135
Merck8$124
Eisai Inc.8$124
Corcept Therapeutics7$115
Abbott8$114
Phathom Pharmaceuticals, Inc.4$97
Daiichi Sankyo Inc.5$92
Aimmune Therapeutics, Inc.4$67
Exact Sciences4$63
Sumitomo Pharma America, Inc.3$62
Esperion Therapeutics, Inc.4$61
Novartis4$60
Boston Scientific2$52
Amarin Pharma, Inc.4$51
Inspire Medical Systems, Inc.2$41
Hologic Sales And Service, LLC2$40
Xeris Pharmaceuticals, Inc.2$36
Dexcom, Inc.2$33
Axsome Therapeutics, Inc.2$31
Kowa Pharmaceuticals America, Inc.2$29
Mayne Pharma Commercial LLC1$24
Kyowa Kirin, Inc.1$24
Amryt Pharma Holdings Ltd1$24
Biogen1$22
Otsuka America Pharmaceutical, Inc.1$20
Chiesi USA, Inc.1$20
Ultragenyx Pharmaceutical Inc.1$20
Actelion Pharmaceuticals US, Inc.1$19
Impel Pharmaceuticals Inc.1$19
Insulet Corporation1$19
Idorsia Pharmaceuticals US Inc1$16
Phadia US Inc.1$15
Mylan Pharmaceuticals Inc.1$15
Cequr Corporation1$14
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$14
Lucid Diagnostics Inc.1$14
Johnson & Johnson1$14
Globus Medical1$13
Lupin Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,086 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$60,397
Medicare patients
243
Services billed
708

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol54$59,250
OzempicSemaglutide35$53,775
Soliqua 100-33Insulin Glargine/Lixisenatide23$43,682
Xigduo XrDapaglifloz Propaned/Metformin29$42,264
MounjaroTirzepatide28$41,307
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$32,748
EliquisApixaban28$28,103
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$18,927
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog19$16,683
JardianceEmpagliflozin11$14,319
Synjardy XrEmpagliflozin/Metformin Hcl16$14,284
MyrbetriqMirabegron18$13,596
TrulancePlecanatide13$6,748
Dexlansoprazole DrDexlansoprazole24$6,729
BelsomraSuvorexant13$5,616

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$790$78,17767 claims
Novo NordiskOzempic$1,014$53,77535 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$252$43,68223 claims
Lilly USA, LLCMounjaro$199$41,30728 claims
GSKTrelegy Ellipta, Shingrix$393$35,38942 claims
Boehringer IngelheimJardiance, Synjardy Xr$312$28,60427 claims
PfizerEliquis$492$28,10328 claims
Astellas Pharma US IncMyrbetriq$375$13,59618 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$292$6,74813 claims
MerckBelsomra$124$5,61613 claims
AbbVieSynthroid$1,376$4,17940 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.

Other family in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →